KAUFMAN, Matthew, Xiao-Jie YAN, Wentian LI, Emanuela M GHIA, Anton W LANGERAK, Laura Z RASSENTI, Chrysoula BELESSI, Neil E KAY, Frederic DAVI, John C BYRD, Šárka POSPÍŠILOVÁ, Jennifer R BROWN, Mark CATHERWOOD, Zadie DAVIS, David OSCIER, Marco MONTILLO, Livio TRENTIN, Richard ROSENQUIST, Paolo GHIA, Jacqueline C BARRIENTOS, Jonathan E KOLITZ, Steven L ALLEN, Kanti R RAI, Kostas STAMATOPOULOS, Thomas J KIPPS, Donna NEUBERG a Nicholas CHIORAZZI. Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. Frontiers in Oncology. Lausanne: Frontiers Media S.A., 2022, roč. 12, July 2022, s. 1-12. ISSN 2234-943X. Dostupné z: https://dx.doi.org/10.3389/fonc.2022.897280.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia
Autoři KAUFMAN, Matthew, Xiao-Jie YAN, Wentian LI, Emanuela M GHIA, Anton W LANGERAK, Laura Z RASSENTI, Chrysoula BELESSI, Neil E KAY, Frederic DAVI, John C BYRD, Šárka POSPÍŠILOVÁ (203 Česká republika, domácí), Jennifer R BROWN, Mark CATHERWOOD, Zadie DAVIS, David OSCIER, Marco MONTILLO, Livio TRENTIN, Richard ROSENQUIST, Paolo GHIA, Jacqueline C BARRIENTOS, Jonathan E KOLITZ, Steven L ALLEN, Kanti R RAI, Kostas STAMATOPOULOS, Thomas J KIPPS, Donna NEUBERG a Nicholas CHIORAZZI.
Vydání Frontiers in Oncology, Lausanne, Frontiers Media S.A. 2022, 2234-943X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30205 Hematology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.700
Kód RIV RIV/00216224:14110/22:00129717
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3389/fonc.2022.897280
UT WoS 000831966100001
Klíčová slova anglicky chronic lymphocytic leukemia; CLL; somatic mutations; immunoglobulin variable domain; prognosis
Štítky 14110212, 14110323, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 13. 12. 2022 10:14.
Anotace
Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively transduce signals to leukemic B cells, B-cell receptor (BCR) signaling is likely at the heart of the worse outcomes of CLL cases without/few IGHV mutations. A corollary of this conclusion is that M-CLL follow less aggressive clinical courses because somatic IGHV mutations have altered BCR structures and no longer bind stimulatory (auto)antigens and so cannot deliver trophic signals to leukemic B cells. However, the latter assumption has not been confirmed in a large patient cohort. We tried to address the latter by measuring the relative numbers of replacement (R) mutations that lead to non-conservative amino acid changes (Rnc) to the combined numbers of conservative (Rc) and silent (S) amino acid R mutations that likely do not or cannot change amino acids, "(S+Rc) to Rnc IGHV mutation ratio". When comparing time-to-first-treatment (TTFT) of patients with (S+Rc)/Rnc <= 1 and >1, TTFTs were similar, even after matching groups for equal numbers of samples and identical numbers of mutations per sample. Thus, BCR structural change might not be the main reason for better outcomes for M-CLL. Since the total number of IGHV mutations associated better with longer TTFT, better clinical courses appear due to the biologic state of a B cell having undergone many stimulatory events leading to IGHV mutations. Analyses of larger patient cohorts will be needed to definitively answer this question.
Návaznosti
NV19-03-00091, projekt VaVNázev: Komplexní prognostický a prediktivní panel pro pacienty s chronickou lymfocytární leukémií: nástroj sekvenování nové generace vhodný pro klinickou praxi i studium genetického pozadí průběhu choroby
Investor: Ministerstvo zdravotnictví ČR, Comprehensive prognostic and predictive panel for chronic lymphocytic leukemia: a next-generation sequencing tool suitable for clinical practice and study of genetic architecture behind the disease progress
VytisknoutZobrazeno: 18. 8. 2024 02:02